Quince Therapeutics, Inc. 8-K

What Happened

• Quince Therapeutics, Inc. (QNCX) filed an 8-K on April 28, 2026 reporting that on April 27, 2026 Nasdaq's Listing Qualifications staff notified the company it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5450(a)(1). Nasdaq found QNCX's common stock had a closing bid of $1.00 or greater for 10 consecutive business days from April 13, 2026 through April 24, 2026, and considers the bid-price matter closed.

Key Details

• Form filed: 8-K filed April 28, 2026 (Item 8.01 — Other Events).
• Bid-price compliance: Closing bid ≥ $1.00 per share for the 10 consecutive business days April 13–24, 2026.
• MVLS noncompliance: Company previously received a notice that its market value of listed securities (MVLS) was below the $50,000,000 requirement under Nasdaq Listing Rule 5450(b)(2)(A).
• Deadline to cure MVLS: Quince has 180 calendar days to regain MVLS compliance, until September 14, 2026.

Why It Matters

• Regaining the $1.00 minimum bid price removes the immediate bid-price delisting risk and keeps the company's listing in good standing on that specific metric. However, the company still must restore the required $50 million market value of listed securities by September 14, 2026 to satisfy Nasdaq’s MVLS test. Failure to regain MVLS compliance by the deadline could lead Nasdaq to take further action, which may include delisting proceedings. Investors should monitor QNCX share price, market capitalization, and company updates for progress on MVLS compliance.